CA-TAULIA
19.12.2022 09:16:35 CET | Business Wire | Press release
A third of global businesses predict the current inflationary environment to continue for more than two years, according to new research from Taulia. Expectations were gloomiest in the UK, with more than two in five (42%) predicting high inflation would last more than two years, while a third (34%) of businesses in Germany, and over a quarter in Singapore (29%) and the US (27%) said the same.
Half of businesses globally (50%) expect today’s inflationary environment to last between one to two years, and nearly two-fifths (37%) of businesses believe inflation will get worse over the next year.
Just 15% of businesses globally predict the current inflationary pressures to last less than 12 months. US firms are most optimistic about this with over a fifth (21%) saying inflation will last less than 12 months, compared to 11% of UK businesses.
Tackling inflation is cited as the top challenge businesses expect to face over the next year. As a result, the findings reveal that businesses are increasing their budgets to prepare for economic uncertainty. Compared to 12 months ago, businesses, on average, have increased their budgets by 13%.
Cedric Bru, CEO, Taulia, comments: “Inflation is having a profound impact on businesses across the globe, causing supply chain disruption, rising costs, and higher borrowing costs. As a result, businesses are having to increase their budgets to help navigate the storm and set themselves up for future survival and success.”
ENDS
Notes to editors:
Research conducted by Opinium among 550 Finance decision makers in the UK, USA, Germany, and Singapore at businesses of USD750million + annual revenue between 10-24 October 2022.
About Taulia
Taulia is a fintech provider of working capital management solutions headquartered in San Francisco, California. Taulia helps companies access value tied up in their payables, receivables, and inventory. A network of more than 2 million businesses use Taulia’s platform to determine when they want to pay and be paid. Taulia enables its customers to execute their working capital strategies, support their suppliers with early payment, and contribute to building sustainable supply chains. Taulia processes more than $500 billion each year and is trusted by the world’s largest companies, including Airbus, AstraZeneca, and Nissan. In March 2022, Taulia became part of SAP. Taulia operates as an independent company with its own brand in the SAP Group.
For more information, please visit www.taulia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005074/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB to Host 2026 Digital Investor Day10.6.2026 14:30:00 CEST | Press release
SLB (NYSE: SLB) will host an Investor Day on Wednesday, June 17, 2026, in New York, where leadership will outline their vision for SLB’s Digital business as digital technologies and AI continue to reshape the energy industry. The presentation will highlight SLB’s integrated digital strategy and portfolio, scalable growth opportunities powered by AI, and financial profile and outlook. Olivier Le Peuch, chief executive officer, SLB, will present at 9:00 a.m. U.S. Eastern Time (ET), and will discuss SLB’s digital strategy and business outlook. Stephane Biguet, chief financial officer, SLB, will present at approximately 11:00 a.m. ET, and will discuss the financial profile of SLB’s Digital business, the market opportunity and SLB’s 2030 digital ambitions. Mr. Le Peuch and Mr. Biguet will be joined by divisional leadership, who will provide further insight into Digital’s competitive differentiation supported by its mission-critical platform, driving transformation for customers. A live webc
Wolters Kluwer expands its Libra AI workspace with authoritative Swiss legal content from leading publisher Stämpfli10.6.2026 14:00:00 CEST | Press release
Collaboration brings trusted Swiss legal expertise directly into AI‑supported legal research, drafting and review Wolters Kluwer Legal & Regulatory today announced the expansion of Libra by Wolters Kluwer, its AI-powered legal workspace, to include professional legal content from Stämpfli Publishers, one of Switzerland’s most respected legal publishers. As a result, Swiss legal professionals using Libra by Wolters Kluwer gain direct access to the legal literature that shapes their daily work – fully integrated into a single AI-supported workflow. The content offering includes commentaries, practitioner guides, yearbooks and selected journals from Stämpfli Publishers – including the renowned “Berner Kommentar”, and the company’s succinct commentaries and legal textbooks. In addition, primary sources of Swiss law at both federal and cantonal level are integrated into the workspace. The offering will be continuously expanded over time, with additional titles gradually integrated into the
Macrobond Launches AI Data Feed with MCP and Skill, Bringing Governed Macroeconomic Intelligence to Enterprise AI Workflows10.6.2026 14:00:00 CEST | Press release
Two new delivery components, MCP for conversational AI and Skill for programmatic access, enable institutions to retrieve trusted, licensed macroeconomic data directly within their AI environments. Macrobond today announced the general availability of the Macrobond AI Data Feed Service, a purpose-built product, enabling financial institutions to integrate governed macroeconomic intelligence directly into AI-powered research, investment, and strategy workflows. Available now with MCP, Skill and API delivery components, the AI Data Feed helps organizations accelerate macroeconomic research and insight generation and reduce reliance on fragmented or ungoverned data sources. By delivering reliable, licensed, economic data integrated directly within AI chat interfaces and coding environments, the AI Data Feed Service provides a trusted foundation for enterprise AI initiatives. As generative AI becomes embedded in research, investment, and strategy workflows, face a foundational challenge: m
Parse Biosciences Launches the Next Generation of its Immune Profiling Kits10.6.2026 14:00:00 CEST | Press release
Updated kits deliver improved sensitivity and receptor recovery for single cell immune repertoire profiling at unprecedented scale Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today launched the next generation of its Evercode™ TCR and Evercode™ BCR kits, shipping to customers worldwide. The updated kits deliver a streamlined workflow, better whole transcriptome sequencing library efficiency, and improved performance, enabling researchers to resolve rare clonotypes and profile immune responses at unprecedented scale. Immunology researchers are working to understand complex adaptive immune responses, but meaningful signals are often rare, transient, or difficult to capture across large, sample-limited studies. Parse's immune profiling portfolio combines scale, sensitivity, and fixation-first workflows with paired TCR or BCR and whole transcriptome profiling, helping researchers connect clonal identity to cell state across high-thro
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region10.6.2026 13:47:00 CEST | Press release
The expanded partnership adds Denmark, Finland, Norway and Sweden to GENESIS Pharma’s existing network of thirteen Southeast European markets.It grants rights for the commercialization of Alnylam’s RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases. GENESIS Pharma, a leading regional biopharma company focused on the commercialization of innovative medicines in Europe, today announced the expansion of its longstanding commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company. The extended agreement broadens the geographical reach of the collaboration to include four Nordic markets -Denmark, Finland, Norway, and Sweden- alongside the thirteen markets in Southeast Europe already within the scope of the partnership. GENESIS Pharma shall commercialize a portfolio of RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases across this expanded territory. The partnership, established
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
